Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Production in Russia (May 2019)

Friday, June 21, 2019

Between January and May 2019, Russia produced 157.5 bln RUB worth of pharmaceutical drugs (manufacturers’ dispatch prices, VAT included), which is in monetary terms (rubles) 19.1% higher than that of the same period in 2018. While the dynamics are positive, they are still significantly lower than those of 2018. These dynamics are due to May’s negative dynamics in monetary terms and low positive in physical terms.

In physical terms, the dynamics for the period are +3.5%, with 1.74 bln units of pharmaceuticals. If calculated in minimum dosage units (MDU), the dynamics are a bit higher, +3.6%. Over the period, Russian pharmaceutical manufacturers dispatched 29.7 bln MDUs.

May 2019 witnessed a typical seasonal drop, while this trend was abandoned in May 2018. The dynamics are -3.8% in monetary terms and +1.9% in physical terms.>/p> The dynamics of OTC drug import in physical terms are -1% for the first 6 months. Among the top 10 companies with the highest dynamics in physical terms, Samaramedprom and Marathon Pharma are the absolute leaders with +56% and +31%, respectively. Pertussinum and Licorice Syrup contributed to the dynamics of Samaramedprom with 6.2 and 3.7 times increases, respectively, and Fluconazole capsules and Rhinorus contributed to the dynamics of Marathon Pharma with 6.9 and 2 times increases.

The dynamics of Rx drug import in physical terms are +11% for the period. Ozon (+59%) and Solopharm (+54%) are noteworthy. Enalapril and Aciclovir contributed to the dynamics of Ozon with 3.6 and 3 times increases. Solutions for injections Meldonium and Calcium Gluconate contributed to the dynamics of Solopharm with 7.9 and 2.3 times increases.

Read more about pharmaceutical drug production in Russia (April 2019) here:

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2018 – May 2019)